vs
CANTALOUPE, INC.（CTLP）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是CANTALOUPE, INC.的1.6倍（$127.1M vs $78.7M），再鼎医药同比增速更快（17.1% vs 6.8%），CANTALOUPE, INC.自由现金流更多（$-614.0K vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 7.7%）
坎塔卢波（原美国技术公司）是一家美国科技企业，核心业务为ePort无现金支付受理技术，依托持专利的PCI合规ePort Connect服务开展运营。该服务可通过无线方式为消费者提供信用卡、借记卡以及Apple Pay、Google Pay等NFC钱包支付选项，同时为运营商提供遥测与机器间通信服务，ePort技术主要应用于...
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
CTLP vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.6倍
$78.7M
营收增速更快
ZLAB
高出10.3%
6.8%
自由现金流更多
CTLP
多$26.1M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
7.7%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $78.7M | $127.1M |
| 净利润 | $-70.0K | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | 2.0% | -54.6% |
| 净利率 | -0.1% | — |
| 营收同比 | 6.8% | 17.1% |
| 净利润同比 | -101.4% | — |
| 每股收益（稀释后） | $0.00 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTLPZLAB
| Q4 25 | $78.7M | $127.1M | ||
| Q3 25 | $80.9M | $115.4M | ||
| Q2 25 | $82.6M | $109.1M | ||
| Q1 25 | $75.4M | $105.7M | ||
| Q4 24 | $73.7M | $108.5M | ||
| Q3 24 | $70.8M | $101.8M | ||
| Q2 24 | $72.7M | $100.1M | ||
| Q1 24 | $67.9M | $87.1M |
净利润CTLPZLAB
| Q4 25 | $-70.0K | — | ||
| Q3 25 | $-919.0K | $-36.0M | ||
| Q2 25 | $6.8M | $-40.7M | ||
| Q1 25 | $49.2M | $-48.4M | ||
| Q4 24 | $5.0M | — | ||
| Q3 24 | $3.6M | $-41.7M | ||
| Q2 24 | $2.2M | $-80.3M | ||
| Q1 24 | $4.7M | $-53.5M |
毛利率CTLPZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | 39.6% | 61.4% |
营业利润率CTLPZLAB
| Q4 25 | 2.0% | -54.6% | ||
| Q3 25 | 2.0% | -42.3% | ||
| Q2 25 | 6.3% | -50.3% | ||
| Q1 25 | 9.1% | -53.3% | ||
| Q4 24 | 8.4% | -62.6% | ||
| Q3 24 | 5.8% | -66.6% | ||
| Q2 24 | 4.9% | -76.0% | ||
| Q1 24 | 6.3% | -80.7% |
净利率CTLPZLAB
| Q4 25 | -0.1% | — | ||
| Q3 25 | -1.1% | -31.2% | ||
| Q2 25 | 8.3% | -37.3% | ||
| Q1 25 | 65.2% | -45.8% | ||
| Q4 24 | 6.7% | — | ||
| Q3 24 | 5.0% | -40.9% | ||
| Q2 24 | 3.0% | -80.2% | ||
| Q1 24 | 6.9% | -61.4% |
每股收益（稀释后）CTLPZLAB
| Q4 25 | $0.00 | $-0.05 | ||
| Q3 25 | $-0.02 | $-0.03 | ||
| Q2 25 | $0.10 | $-0.04 | ||
| Q1 25 | $0.65 | $-0.04 | ||
| Q4 24 | $0.07 | $-0.09 | ||
| Q3 24 | $0.04 | $-0.04 | ||
| Q2 24 | $0.03 | $-0.08 | ||
| Q1 24 | $0.06 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $53.0M | $689.6M |
| 总债务越低越好 | $37.7M | — |
| 股东权益账面价值 | $252.5M | $715.5M |
| 总资产 | $381.9M | $1.2B |
| 负债/权益比越低杠杆越低 | 0.15× | — |
8季度趋势，按日历期对齐
现金及短期投资CTLPZLAB
| Q4 25 | $53.0M | $689.6M | ||
| Q3 25 | $55.0M | $717.2M | ||
| Q2 25 | $51.1M | $732.2M | ||
| Q1 25 | $46.3M | $757.3M | ||
| Q4 24 | $27.7M | $779.7M | ||
| Q3 24 | $33.1M | $616.1M | ||
| Q2 24 | $58.9M | $630.0M | ||
| Q1 24 | $50.2M | $650.8M |
总债务CTLPZLAB
| Q4 25 | $37.7M | — | ||
| Q3 25 | $38.3M | — | ||
| Q2 25 | $38.7M | — | ||
| Q1 25 | $39.2M | — | ||
| Q4 24 | $37.0M | — | ||
| Q3 24 | $37.3M | — | ||
| Q2 24 | $37.5M | — | ||
| Q1 24 | $38.1M | — |
股东权益CTLPZLAB
| Q4 25 | $252.5M | $715.5M | ||
| Q3 25 | $251.8M | $759.9M | ||
| Q2 25 | $251.0M | $791.7M | ||
| Q1 25 | $240.7M | $810.8M | ||
| Q4 24 | $190.1M | $840.9M | ||
| Q3 24 | $186.2M | $667.7M | ||
| Q2 24 | $181.7M | $704.2M | ||
| Q1 24 | $178.8M | $762.2M |
总资产CTLPZLAB
| Q4 25 | $381.9M | $1.2B | ||
| Q3 25 | $389.5M | $1.2B | ||
| Q2 25 | $381.9M | $1.2B | ||
| Q1 25 | $370.5M | $1.2B | ||
| Q4 24 | $303.0M | $1.2B | ||
| Q3 24 | $312.1M | $985.3M | ||
| Q2 24 | $335.6M | $987.4M | ||
| Q1 24 | $319.9M | $988.4M |
负债/权益比CTLPZLAB
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.15× | — | ||
| Q2 25 | 0.15× | — | ||
| Q1 25 | 0.16× | — | ||
| Q4 24 | 0.19× | — | ||
| Q3 24 | 0.20× | — | ||
| Q2 24 | 0.21× | — | ||
| Q1 24 | 0.21× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.1M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $-614.0K | $-26.7M |
| 自由现金流率自由现金流/营收 | -0.8% | -21.0% |
| 资本支出强度资本支出/营收 | 4.8% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $25.8M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流CTLPZLAB
| Q4 25 | $3.1M | $-26.0M | ||
| Q3 25 | $7.0M | $-32.0M | ||
| Q2 25 | $9.4M | $-31.0M | ||
| Q1 25 | $22.4M | $-61.7M | ||
| Q4 24 | $522.0K | $-55.8M | ||
| Q3 24 | $-12.0M | $-26.8M | ||
| Q2 24 | $14.3M | $-42.2M | ||
| Q1 24 | $14.7M | $-90.1M |
自由现金流CTLPZLAB
| Q4 25 | $-614.0K | $-26.7M | ||
| Q3 25 | $3.5M | $-35.0M | ||
| Q2 25 | $4.3M | $-33.9M | ||
| Q1 25 | $18.6M | $-63.2M | ||
| Q4 24 | $-3.8M | $-58.4M | ||
| Q3 24 | $-15.8M | $-28.2M | ||
| Q2 24 | $8.5M | $-42.9M | ||
| Q1 24 | $11.4M | $-91.1M |
自由现金流率CTLPZLAB
| Q4 25 | -0.8% | -21.0% | ||
| Q3 25 | 4.4% | -30.4% | ||
| Q2 25 | 5.3% | -31.1% | ||
| Q1 25 | 24.6% | -59.9% | ||
| Q4 24 | -5.1% | -53.8% | ||
| Q3 24 | -22.3% | -27.7% | ||
| Q2 24 | 11.7% | -42.9% | ||
| Q1 24 | 16.9% | -104.5% |
资本支出强度CTLPZLAB
| Q4 25 | 4.8% | 0.5% | ||
| Q3 25 | 4.2% | 2.6% | ||
| Q2 25 | 6.2% | 2.6% | ||
| Q1 25 | 5.1% | 1.5% | ||
| Q4 24 | 5.8% | 2.4% | ||
| Q3 24 | 5.4% | 1.3% | ||
| Q2 24 | 7.9% | 0.7% | ||
| Q1 24 | 4.8% | 1.1% |
现金转化率CTLPZLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 1.38× | — | ||
| Q1 25 | 0.46× | — | ||
| Q4 24 | 0.10× | — | ||
| Q3 24 | -3.36× | — | ||
| Q2 24 | 6.47× | — | ||
| Q1 24 | 3.16× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTLP
| Transaction Processing | $47.9M | 61% |
| Subscription Revenue | $21.8M | 28% |
| Products | $9.0M | 11% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
